Difference between revisions of "Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative"
Jump to navigation
Jump to search
imported>Medgirl131 |
|||
| Line 1: | Line 1: | ||
| − | {| class="wikitable sortable mw-collapsible mw-collapsed" style="width:700px; text-align:left; margin-left:auto; margin-right:auto; border:none;" | + | {| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="width:700px; text-align:left; margin-left:auto; margin-right:auto; border:none;" |
| − | |+ class="nowrap" | Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the {{abbr|WHI|Women's Health Initiative}} | + | |+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the {{abbr|WHI|Women's Health Initiative}} |
|- | |- | ||
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}*) !! style="width: 75px;" data-sort-type="number" | Placebo<br />(n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}}<br />(n = 8506) | ! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}*) !! style="width: 75px;" data-sort-type="number" | Placebo<br />(n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}}<br />(n = 8506) | ||
| Line 31: | Line 31: | ||
|- class="sortbottom" | |- class="sortbottom" | ||
| colspan="10" style="width: 1px;" | WHI = [[Women's Health Initiative]]. CEEs = [[Conjugated estrogens]]. MPA = [[Medroxyprogesterone acetate]].<br /><sup>a</sup> = Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer. <sup>b</sup> = A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes. <sup>c</sup> = Not included in Global Index. * = Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. '''Sources:'''<ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref> | | colspan="10" style="width: 1px;" | WHI = [[Women's Health Initiative]]. CEEs = [[Conjugated estrogens]]. MPA = [[Medroxyprogesterone acetate]].<br /><sup>a</sup> = Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer. <sup>b</sup> = A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes. <sup>c</sup> = Not included in Global Index. * = Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. '''Sources:'''<ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref> | ||
| − | |} | + | |}<!-- |
| + | |||
| + | --><noinclude> | ||
| + | ==References== | ||
| + | {{Reflist}} | ||
| + | [[Category:Medication templates]] | ||
| + | [[Category:Templates that generate named references]] | ||
| + | </noinclude> | ||
Revision as of 03:04, 11 November 2018
| Event | Relative Risk CEEs/MPA vs. placebo at 5.2 years (95% CI*) | Placebo (n = 8102) |
CEEs/MPA (n = 8506) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Absolute Risk per 10,000 Women-Years | |||||||||
| Coronary heart disease events Non-fatal myocardial infarction Coronary heart disease death |
1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) |
30 23 6 |
37 30 7 | ||||||
| Invasive breast cancera | 1.26 (1.00–1.59) | 30 | 38 | ||||||
| Stroke | 1.41 (1.07–1.85) | 21 | 29 | ||||||
| Pulmonary embolism | 2.13 (1.39–3.25) | 8 | 16 | ||||||
| Colorectal cancer | 0.63 (0.43–0.92) | 16 | 10 | ||||||
| Endometrial cancer | 0.83 (0.47–1.47) | 6 | 5 | ||||||
| Hip fracture | 0.66 (0.45–0.98) | 15 | 10 | ||||||
| Death due to causes other than above | 0.92 (0.74–1.14) | 40 | 37 | ||||||
| Global Indexb | 1.15 (1.03–1.28) | 151 | 170 | ||||||
| Deep vein thrombosisc | 2.07 (1.49–2.87) | 13 | 26 | ||||||
| Vertebral fracturesc | 0.66 (0.44–0.98) | 15 | 9 | ||||||
| Other osteoporotic fracturesc | 0.77 (0.69–0.86) | 170 | 131 | ||||||
| WHI = Women's Health Initiative. CEEs = Conjugated estrogens. MPA = Medroxyprogesterone acetate. a = Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer. b = A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes. c = Not included in Global Index. * = Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. Sources:[1][2] | |||||||||
References
- ↑ Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). fda.gov. Retrieved 27 November 2016.
- ↑ Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial". JAMA. 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397.